ECOR electroCore

electroCore to Announce Fourth Quarter and Full Year Ended December 31, 2023 Financial Results on Wednesday, March 13, 2024

electroCore to Announce Fourth Quarter and Full Year Ended December 31, 2023 Financial Results on Wednesday, March 13, 2024

ROCKAWAY, N.J., March 05, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial results for the fourth quarter and year ended December 31, 2023, after the close of the market on Wednesday, March 13, 2024. Management will host a conference call and webcast at 4:30 PM EST to discuss the financial results and answer questions.

Wednesday, March 13, 4:30 PM EST

Domestic: 877-407-8835

International:

Conference ID: 13744117

Webcast: 

About electroCore, Inc.

electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving health through its non-invasive vagus nerve stimulation (“nVNS”) technology platform. Our focus is the commercialization of medical devices for the management and treatment of certain medical conditions and consumer product offerings utilizing nVNS to promote general wellbeing and human performance in the United States and select overseas markets.

For more information, visit .

Contact:

ECOR Investor Relations

(973) 302-9253



EN
05/03/2024

Underlying

ECORelectroCore

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on electroCore

 PRESS RELEASE
Free
ECOR ELECTROCORE

electroCore Announces the Launch of Truvaga Plus® for General Wellness

electroCore Announces the Launch of Truvaga Plus® for General Wellness ROCKAWAY, N.J., April 08, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the launch of its direct-to-consumer mobile app-enabled product for general wellness, Truvaga Plus, which will be available on beginning April 8, 2024. Our first general wellness product, Truvaga 350, exceeded our expectations and Truvaga Plus will be an exciting addition to the Truvaga brand. Truvaga Plus is engineered to seamlessly integrate into daily ...

April 8, 2024 1 EN
 PRESS RELEASE
Free
ECOR ELECTROCORE

electroCore Expands Intellectual Property Portfolio

electroCore Expands Intellectual Property Portfolio electroCore Granted Two New U.S. Patents ROCKAWAY, N.J., April 02, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it has received patent issue notifications from the United States Patent and Trademark Office (USPTO). The two patents were issued on April 2, 2024, and relate to electroCore’s non-invasive vagus nerve stimulation (nVNS) technology: US Patent No. 11,944,815 entitled “Non-Invasive Nerve Stimulation with Mobile Device” generall...

April 2, 2024 1 EN
 PRESS RELEASE
Free
ECOR ELECTROCORE

electroCore Announces Fourth Quarter and Full Year 2023 Financial Resu...

electroCore Announces Fourth Quarter and Full Year 2023 Financial Results Record full year 2023 net sales of $16.0 million increased 87% over $8.6 million for the full year 2022 Company to host conference call and webcast today, March 13, 2024 at 4:30pm EST ROCKAWAY, N.J., March 13, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (the “Company”), a commercial-stage bioelectronic medicine and wellness company, today announced fourth quarter and full year 2023 financial results. Fourth Quarter 2023 and Recent Highlights Reported record full year of 2023 revenue of $16.0 millio...

March 13, 2024 1 EN
 PRESS RELEASE
Free
ECOR ELECTROCORE

electroCore to Participate in Upcoming Investor Conferences

electroCore to Participate in Upcoming Investor Conferences ROCKAWAY, N.J., March 12, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that the Company’s Chief Strategy Officer, Joshua Lev, is scheduled to attend the 36th Annual Roth Conference taking place at The Ritz Carlton Laguna Niguel in Dana Point, California on March 17 – 19, 2024. electroCore will host 1x1 investor meetings on March 18 and 19, 2024. Please contact Roth MKM to schedule a 1x1 meeting. In addition, Dan Goldberger, CEO of elect...

March 12, 2024 1 EN
 PRESS RELEASE
Free
ECOR ELECTROCORE

electroCore to Announce Fourth Quarter and Full Year Ended December 31...

electroCore to Announce Fourth Quarter and Full Year Ended December 31, 2023 Financial Results on Wednesday, March 13, 2024 ROCKAWAY, N.J., March 05, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial results for the fourth quarter and year ended December 31, 2023, after the close of the market on Wednesday, March 13, 2024. Management will host a conference call and webcast at 4:30 PM EST to discuss the financial results and answer questions. Wednesday, March 13, 4:30 PM ...

March 5, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch